Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Exelixis Inc (EXEL)

Exelixis Inc (EXEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,506,926
  • Shares Outstanding, K 285,579
  • Annual Sales, $ 1,830 M
  • Annual Income, $ 207,770 K
  • EBIT $ 523 M
  • EBITDA $ 549 M
  • 60-Month Beta 0.52
  • Price/Sales 5.19
  • Price/Cash Flow 43.74
  • Price/Book 4.23

Options Overview Details

View History
  • Implied Volatility 32.20% ( -6.17%)
  • Historical Volatility 24.26%
  • IV Percentile 10%
  • IV Rank 25.48%
  • IV High 72.42% on 08/05/24
  • IV Low 18.44% on 11/08/24
  • Put/Call Vol Ratio 0.72
  • Today's Volume 547
  • Volume Avg (30-Day) 1,151
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 44,410
  • Open Int (30-Day) 46,296

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 21 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.40
  • Number of Estimates 10
  • High Estimate 0.52
  • Low Estimate 0.19
  • Prior Year 0.27
  • Growth Rate Est. (year over year) +48.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
33.11 +0.54%
on 12/20/24
36.97 -9.95%
on 11/29/24
-1.36 (-3.92%)
since 11/20/24
3-Month
25.17 +32.24%
on 10/10/24
36.97 -9.95%
on 11/29/24
+6.87 (+26.00%)
since 09/20/24
52-Week
19.20 +73.39%
on 01/08/24
36.97 -9.95%
on 11/29/24
+10.07 (+43.37%)
since 12/20/23

Most Recent Stories

More News
Lilly Announces New $15B Stock Buyback Plan, Ups Dividend by 15%

Eli Lilly and Company LLY announced that its board of directors approved a new $15 billion share buyback plan. The earlier $5 billion stock repurchase plan ended in the fourth quarter of 2024.The board...

LLY : 767.76 (+1.35%)
EXEL : 33.29 (-1.16%)
GILD : 92.57 (+1.62%)
PFE : 26.36 (+2.29%)
AZN's Bladder Cancer sBLA for Imfinzi Gets FDA's Priority Tag

AstraZeneca AZN announced that the FDA has accepted and granted priority review to its supplemental biologics license application (sBLA) seeking expanded use of its blockbuster drug, Imfinzi (durvalumab),...

AZN : 65.35 (+1.41%)
EXEL : 33.29 (-1.16%)
GILD : 92.57 (+1.62%)
PFE : 26.36 (+2.29%)
2 Biotech Stocks to Buy Hand Over Fist in December

The biotech industry has lagged the broader market so far in 2024. The SPDR S&P Biotech ETF, an industry benchmark, is up 9% this year compared to 28% for the S&P 500 . Will that trend continue in 2025?...

CRSP : 40.72 (+0.83%)
EXEL : 33.29 (-1.16%)
Insider Sale: EVP & General Counsel of $EXEL (EXEL) Sells 60,000 Shares

Jeffrey Hessekiel, the EVP & General Counsel of $EXEL ($EXEL), sold 60,000 shares of the company on 11-29-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

EXEL : 33.29 (-1.16%)
Insider Sale: EVP of $EXEL (EXEL) Sells 10,000 Shares

Patrick J. Haley, the EVP of $EXEL ($EXEL), sold 10,000 shares of the company on 11-22-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately 3.5% of their shares....

EXEL : 33.29 (-1.16%)
3 Magnificent Stocks Under $100 to Buy in November

The price could be right for these stocks.

AZN : 65.35 (+1.41%)
SMMT : 17.87 (-2.88%)
MRK : 98.05 (-1.48%)
EXEL : 33.29 (-1.16%)
Exelixis (EXEL) Q3 2024 Earnings Call Transcript

EXEL earnings call for the period ending September 30, 2024.

EXEL : 33.29 (-1.16%)
Exelixis: Q3 Earnings Snapshot

Exelixis: Q3 Earnings Snapshot

EXEL : 33.29 (-1.16%)
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma

For Immediate ReleaseChicago, IL – October 25, 2024 – Today, Zacks Equity Research discusses Exelixis, Inc, EXEL, Blueprint Medicines BPMC, CRISPR Therapeutics CRSP, Amicus Therapeutics FOLD and Verona...

FOLD : 9.80 (+0.72%)
CRSP : 40.72 (+0.83%)
VRNA : 42.02 (+1.94%)
EXEL : 33.29 (-1.16%)
BPMC : 90.14 (+1.36%)
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright

It has been a decent year for the biotech industry so far, buoyed by new drug approvals and positive regulatory/pipeline updates. The third-quarter earnings season has just kicked off, with most major...

FOLD : 9.80 (+0.72%)
CRSP : 40.72 (+0.83%)
VRNA : 42.02 (+1.94%)
EXEL : 33.29 (-1.16%)
BPMC : 90.14 (+1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exelixis, Inc. is an oncology-focused biotechnology company, which primarily focuses on the discovery, development and commercialization of new drugs for the treatment of difficult-to-treat cancers. The company has four approved drugs in its portfolio. Of these, two are derived from cabozantinib, the...

See More

Key Turning Points

3rd Resistance Point 34.18
2nd Resistance Point 33.93
1st Resistance Point 33.61
Last Price 33.29
1st Support Level 33.04
2nd Support Level 32.79
3rd Support Level 32.47

See More

52-Week High 36.97
Last Price 33.29
Fibonacci 61.8% 30.18
Fibonacci 50% 28.09
Fibonacci 38.2% 25.99
52-Week Low 19.20

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar